Cancer clinical trials in the region Provence-Alpes-Côte d'Azur
391 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Early Access
Liver and bile duct cancer
Required histologic sub types
Intrahepatic cholangiocarcinoma
Extrahepatic cholangiocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Jazz Pharmaceuticals
Early Access
Bladder / Urinary Tract / Urethral cancer
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Merck Sharp & Dohme LLC
Early Access
Bladder / Urinary Tract / Urethral cancer
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Astellas Pharma Développement mondial, Inc.
Early Access
Kidney cancer
Pancreas cancer
Required histologic types
Clear cell carcinoma
Required histologic sub types
Neuroendocrine tumor
Required disease stage
Localized
Required genetic anomalies
Von Hippel-Lindau syndrome (VHL)
1 recruiting site
Merck Sharp & Dohme LLC
Early Access
Lymphoma
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required number of previous lines of therapy
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
Hoffmann-La Roche
Early Access
Lung cancer
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Janssen
Phase 3
Breast cancer
#NCT05696626
#2023-503708-10-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ESR
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Targeted therapy
Hormone therapy
Excluded genetic anomalies
Other mutation
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Sermonix Pharmaceuticals Inc.
Phase 3
Amyloidosis
#NCT07207811
#2024-518899-31-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
19 recruiting sites
Novo Nordisk A/S
Phase 3
Liver and bile duct cancer
#NCT07221253
#2025-523085-24-00
Required histologic sub types
Intrahepatic cholangiocarcinoma
Extrahepatic cholangiocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
4 recruiting sites
AstraZeneca
Phase 3
Lung cancer
#NCT06312137
#2023-508012-35-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
10 recruiting sites
Merck Sharp & Dohme LLC